Process Control, Automation, and PAT

Nathan Pettus, president of Process Systems and Solutions at Emerson, discusses how automation is impacting recent sustainability technologies and solutions.

Organizations can better understand the maturity of AI-driven automation technology across their organization’s IT landscape through effective pharmacovigilance.

Shifts in pharmaceutical packaging have spurred tremendous growth in the pre-filled syringe fill/finish industry.

Through the integration of human expertise, artificial intelligence, and automation robotics, bio/pharma companies can more efficiently target drug discovery efforts with bigger payoff.

Through collaboration and transparency, engineering and automation companies can achieve great efficiencies and success for their customer by integrating intelligent design into a facility.

By taking a digital maturity-first approach to Pharma 4.0, manufacturers can optimally position themselves for success.

Leveraging smart technology and SMEs for significant operational and financial benefits.

Automation enables intensification of downstream processes.

Automation and digitalization work together in the digital plant.

Merck has entered into a collaboration with Agilent Technologies with the aim of filling the industry gap in PAT for downstream processing.

This article summarizes industry views on PAT in bioprocess-related applications and presents a vision for the biopharmaceutical industry to achieve Industry 4.0.

As process controls adjust to a continuously shifting manufacturing landscape, implementation of information gathered from novel data analysis techniques has become a priority.

The integration of modern software tools can make the acquisition and analysis of MS data more efficient, accurate, and compliant.

Recent trends in data analytics highlight the use of modeling techniques to improve process control and monitoring in biopharmaceutical production.

The growing use of automation and digitalization technologies push cell culture bioprocessing forward.

Lighthouse manufacturing techniques utilize technology and automation to streamline production.

Fosun Pharma and Insilico Medicine will collaborate on AI-driven drug discovery and development of product candidates targeting multiple disease targets.

Modeling techniques can improve process control and monitoring in biopharmaceutical production.

Upstream processing is better optimized with the help of automated workflows.

Qualified algorithms enable validation of machine learning models that can be used for process optimization.

Fully automated enzyme analysis can ease a persistent bottleneck in biocatalyst development for bio/pharmaceutical applications.

Timing is everything, and it might be ideal for acceleration of real-time monitoring solutions.

Glycosylation monitoring has been heavily dependent on manual processes, but the automation of sample preparation streamlines the overall workflow.

Synthace has raised $35 million in funding to fuel growth of its life sciences R&D technology.

GenScript’s new gene synthesis center in Piscataway, NJ, is highly automated to accelerate production time and increase supply chain resiliency for biopharma and synthetic biology.

The adoption of perfusion cell culture continues to advance with the help of PAT tools.

Early control architecture decisions can impact a facility’s long-term growth, flexibility, and efficiency.

Advancements in bioprocessing technologies test microbial fermentation adaptability.

The industry considers applying automation and digitalization lessons learned during the COVID-19 pandemic to enhance workflows.

Mechanistic models provide process understanding for developing robust manufacturing processes and for scale up and tech transfer.